Altamira Therapeutics believes it has key advantages as it focuses on developing RNA therapeutics

Altamira Therapeutics (NASDAQ:CYTO) CEO Dr Thomas Meyer says the company has used last year's acquisition of Trasir Therapeutics to strategically focus its business on the development of RNA therapeutics.

Meyer told Proactive the focus on RNA therapeutics will see it spinning off or divesting its legacy businesses in neurotology, rhinology and allergology.